Host: John J. Russell, MD 

Guest: Axel Grothey, MD 


 Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal cancer is Dr. Axel Grothey.

Host: John J. Russell, MD Guest: Axel Grothey, MD Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal cancer is Dr. Axel Grothey.

mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
 
 Sponsored by

Medicine

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location. To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC). This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only. Sponsored by

Between 50 and 60 percent of patients diagnosed with colorectal cancer will develop metastases during the course of their disease, spreading to the lungs, liver, or other secondary location.
To help physicians tackle this very real threat facing their patients, Conversations on Colorectal Cancer focuses on the current guidelines and therapeutic landscape for metastatic colorectal cancer (mCRC).
This non-certified educational series is sponsored by Lilly. Content for this series is produced and controlled by ReachMD. This series is intended for healthcare professionals only.
&nbsp;
&nbsp;Sponsored by

Share mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know

Sign up to save your podcasts

mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know

mCRC ‘State of the Union’: Current & Emerging Research Avenues to Know